Search
Showing results for "1"
Research
International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency DisorderCDKL5 Deficiency Disorder (CDD) is a rare, X-linked dominant condition that causes a developmental and epileptic encephalopathy (DEE). The incidence is between ~ 1:40,000 and 1:60,000 live births. Pathogenic variants in CDKL5 lead to seizures from infancy and severe neurodevelopmental delay.
Research
A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosisThe marked heterogeneity in cystic fibrosis (CF) disease complicates the selection of those most likely to benefit from existing or emergent treatments. We aimed to predict the progression of bronchiectasis in preschool children with CF.
News & Events
Meet MikeMeet Professor Mike Riddell. Mike is the co-founder of the Physical Activity and Diabetes Unit at York University in Toronto recently visited Perth to share his research on exercise and type 1 diabetes at the Children’s Diabetes Centre Community Forum.
News & Events
Do you need more insulin for the protein and fat in your meal?Current Type 1 Diabetes management guidelines recommend adjusting insulin doses for food based on the amount of carbohydrate eaten at each meal.
Research
Intranasal Insulin Trial IIIf successful, this vaccine could prevent type 1 diabetes and the need for daily insulin injections in people at risk.
Research
Vector fields of risk: A new approach to the geographical representation of childhood asthmaOne of the major challenges in health studies with a spatial dimension is to produce valid and meaningful geographical representations of risk.
Research
WALLABY Pre-pilot Survey: The Effects of Tidal Interaction on Radial Distribution of Color in Galaxies of the Eridanus SupergroupWe study the tidal interaction of galaxies in the Eridanus supergroup, using H i data from the pre-pilot survey of the Widefield ASKAP L-band Legacy All-sky Blind surveY.
Research
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive CombinationsAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.
Research
"i Think i Could Have Used It Better": Experiences of Youth with High HbA1c Commencing Advanced Hybrid Closed-Loop Therapy in a Clinical Trial Setting - A Qualitative ResearchAdvanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.
Research
Hand function development of children with hemiplegic cerebral palsy: A scoping reviewHemiplegic cerebral palsy (hCP) typically impacts sensorimotor control of the hand, but comprehensive assessments of the hands of children with hCP are relatively rare. This scoping review summarizes the development of hand function for children with hCP.